SmithKline Beecham buys Maltova and Viva - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SmithKline Beecham buys Maltova and Viva

Feb 9, 2000

SmithKline Beecham Consumer is buying out the 'Maltova' and 'Viva' brands from Jagatjit Industries for a consideration of Rs 863 m. SmithKline Beecham Consumer Healthcare (SBCH) manufactures malted food under the brand names Horlicks and Boost. Its product range also includes 'Gopika' ghee and biscuits. Horlicks commands 54% market share, while Boost has 10% market share.

The acquisition, which was rumoured to have taken place in December itself, has been made official only now. The move will add 6% to the company's market share and strengthen the company's presence in the northern markets. This acquisition also reflects on the parents interest in the company, that had become suspect after it set up a 100% subsidiary on India.

Competition in the malted food drink segment has been becoming increasingly intense with both Nestle and Cadbury increasing their promotion expenditures. Although SBCH will gain market share, it will have to increase its advertising expenditure significantly. This could adversely affect margins.


Equitymaster requests your view! Post a comment on "SmithKline Beecham buys Maltova and Viva". Click here!

  

More Views on News

SYNGENE INTERNATIONAL at 52 Week High; BSE 500 Index Down 1.5 % (Market Updates)

Sep 24, 2020 | Updated on Sep 24, 2020

SYNGENE INTERNATIONAL share price has hit a 52-week high. It is presently trading at Rs 597. BSE 500 Index is down by 1.5% at 14,465. Within the BSE 500, SYNGENE INTERNATIONAL (up 5.5%) and GSK CONSUMER (up 5.1%) are among the top gainers, while top losers are SHRIRAM TRANSPORT and INDIABULLS REAL EST.

GSK CONSUMER Announces Quarterly Results (3QFY20); Net Profit Up 25.1% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.1% YoY). Sales on the other hand came in at Rs 12 bn (up 3.8% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

GSK CONSUMER Announces Quarterly Results (2QFY20); Net Profit Up 25.3% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, GSK CONSUMER has posted a net profit of Rs 3 bn (up 25.3% YoY). Sales on the other hand came in at Rs 13 bn (up 5.7% YoY). Read on for a complete analysis of GSK CONSUMER's quarterly results.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GSK CONSUMER SHARE PRICE


Apr 15, 2020 (Close)

TRACK GSK CONSUMER

  • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK CONSUMER 5-YR ANALYSIS

COMPARE GSK CONSUMER WITH

MARKET STATS